1、 : : 120 , 60 ; 12 : 12 , TBIL ALP GGT 4 (P0.05) , 1.2 2010 3 2470 1.3 , 1.4 ( : ; :H20100502; :250 mg/ ) , 3 / , , 3 /d ( : ; :Z20120125; :500 mg/ ) , 3 / , , 3 /d 12 , 1.5 (TBIL ALT AST ALP - (HA LN -C 1.6 4 2010 : , : , 10%49% : , = + 1.7 SPSS16.0 , (%) , , , t P0.05 2 2.1 , (P0.05) , TBIL ALP GG
2、T , (P0.05) 1 1 2.2 , (P0.05) , (P0.05) 2 2 2.3 90.0% 66.7%, , (P0.05) 3 3 3 , , , , , , , , , , 5 , , , , , 6 , , , , 6 , , , , ; , 8; ; , 9; ; 10 , , , , , , , , 1 , , , . J. , 2013, 10 (12) :1417-1424. 2 , , . 30 J. , 2012, 28 (2) :269-270, 276. 3 . (2010 ) J. , 2010, 15 (10) :617-621. 4 , , . J.
3、 , 2011, 8 (20) :113-114. 5 , , . J. , 2014, 14 (08) :991-998. 6Lindor KD, Gershwin ME, Poupon R, et al.Primary Biliary Cirrhosis-AASLD Practice GuadelinesJ.Hepatology, 2013, 50 (1) :291-308. 7Prince M, Chetwynd A, Newman W, et al.Surval and symptom progression in a geographically based cohort of pa
4、tients with primary biliary cirhosis:follow-up for up to 28 yearJ.Gastroenterology, 2012, 123 (20) :1044-1051. 8 , , . J. , 2012, 15 (31) :3624-3627. 9Jorgensen R, Angulo P, Dickson ER, et al.Results of long-term ursodiol treatment for patients with primary biliary cirrhosisJ.Am J Gastroenterl, 2012, 97 (14) :2647-2650. 10Lazaridis KN, Gores GJ, Lindor KD.Uresodeoxy cholic acid mechamism of action and clinical use in hepatobiliary disordersJ.Hepatol, 2013, 35 (15) :134-146.
